SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
SciSparc Ltd., today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.
Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies.
Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives. SciSparc aims to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector.
Also Read:Â Genpact Launches Agentic Accounts Receivable Suite to Optimize Cash Flow and Working Capital
The Company will continue to evaluate opportunities in the field as it pursues its strategic shift. There can be no assurance that these efforts will result in any transaction, commercial agreement or revenue-generating activity for the Company.
Also Read:Â Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Board of Directors
About SciSparc Ltd. :
The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
Write to us Letstalk@ittechpulse.comto learn more about our exclusive editorial packages and programmes.
